CN103974711A - 抗癌融合蛋白 - Google Patents

抗癌融合蛋白 Download PDF

Info

Publication number
CN103974711A
CN103974711A CN201280058346.6A CN201280058346A CN103974711A CN 103974711 A CN103974711 A CN 103974711A CN 201280058346 A CN201280058346 A CN 201280058346A CN 103974711 A CN103974711 A CN 103974711A
Authority
CN
China
Prior art keywords
seq
sequence
fusion protein
domain
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280058346.6A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·皮耶奇克兰
S·帕夫拉克
M·希玛尼克
A·M·皮耶切科兰
B·M·泽雷克
P·鲁兹加
A·R·亚沃尔斯基
M·I·特斯克-卡明斯卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamed Sp zoo
Original Assignee
Adamed Sp zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp zoo filed Critical Adamed Sp zoo
Publication of CN103974711A publication Critical patent/CN103974711A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201280058346.6A 2011-11-28 2012-11-28 抗癌融合蛋白 Pending CN103974711A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne
PLP.397167 2011-11-28
PCT/IB2012/056806 WO2013080147A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
CN103974711A true CN103974711A (zh) 2014-08-06

Family

ID=47561689

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280058346.6A Pending CN103974711A (zh) 2011-11-28 2012-11-28 抗癌融合蛋白

Country Status (18)

Country Link
US (1) US20150044162A1 (https=)
EP (1) EP2785362A2 (https=)
JP (1) JP2015500228A (https=)
KR (1) KR20140097529A (https=)
CN (1) CN103974711A (https=)
AU (1) AU2012345494A1 (https=)
BR (1) BR112014012808A2 (https=)
CA (1) CA2856480A1 (https=)
EA (1) EA201491049A1 (https=)
HK (1) HK1201727A1 (https=)
IL (1) IL232743A0 (https=)
IN (1) IN2014CN04498A (https=)
MX (1) MX2014006369A (https=)
PH (1) PH12014501083A1 (https=)
PL (1) PL397167A1 (https=)
SG (1) SG11201402312WA (https=)
WO (1) WO2013080147A2 (https=)
ZA (1) ZA201404667B (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
WO2017000913A1 (zh) * 2015-07-02 2017-01-05 马卫红 用于肿瘤靶向治疗的白细胞介素15融合蛋白
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
CN112105631A (zh) * 2018-03-06 2020-12-18 约翰霍普金斯大学 Treg耗尽和检查点抑制剂的组合
CN113354738A (zh) * 2020-03-05 2021-09-07 宁波德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
CN114681599A (zh) * 2020-12-31 2022-07-01 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
CN117384859A (zh) * 2023-12-13 2024-01-12 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
JP6935195B2 (ja) * 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN106604934A (zh) * 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
EP3253799B1 (en) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
EP3303373B1 (en) * 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
KR101732126B1 (ko) 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
WO2020234498A2 (es) * 2019-05-15 2020-11-26 Universidad De Granada Terapia génica con los genes hokd y ldrb para el tratamiento del cáncer
JP7818834B2 (ja) * 2020-08-17 2026-02-24 エーティービー セラピューティクス リボトキシンまたはＲＮＡｓｅを含む組換え免疫毒素
WO2023013785A1 (ja) * 2021-08-06 2023-02-09 花王株式会社 Ｓｎａｒｅを活用した核酸構築物
CN118792375B (zh) * 2024-06-25 2025-09-23 华南农业大学 一种具有补肾壮阳功效的瓜蒌多肽及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1609124A (zh) * 2003-10-22 2005-04-27 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2010005519A1 (en) * 2008-06-30 2010-01-14 University Of Pennsylvania Fn14/trail fusion proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
AU2001238501A1 (en) 2000-02-16 2001-08-27 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1688498B1 (en) 2003-11-03 2011-03-09 Beijing Sunbio Biotech Co., Ltd. A recombinant protein with cancer suppression action, its encoding gene and use
US7252993B2 (en) 2004-03-12 2007-08-07 Battelle Energy Alliance, Llc Plasmids encoding therapeutic agents
ES2372537T3 (es) 2005-07-29 2012-01-23 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
CN101287990B (zh) 2005-08-16 2012-07-04 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
EP2079840A4 (en) 2006-10-30 2010-06-30 Viventia Biotech Inc IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN
EP2097529A4 (en) 2006-12-29 2010-03-24 Osprey Pharmaceuticals Usa Inc METHOD FOR SELECTION AND PRODUCTION OF MODIFIED TOXINS, MODIFIED TOXINE CONJUGATES AND USES THEREOF
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1609124A (zh) * 2003-10-22 2005-04-27 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2010005519A1 (en) * 2008-06-30 2010-01-14 University Of Pennsylvania Fn14/trail fusion proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KREITMAN RJ: "Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies", 《BIODRUGS》 *
LI JF ET AL.: "induction of apoptosis by gene transfer of human TRAIL mediated by arginine-rich intracellular delivery peptides", 《ANTICANCER RES》 *
SHIN J N ET AL.: "Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases", 《EXP CELL RES》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
WO2017000913A1 (zh) * 2015-07-02 2017-01-05 马卫红 用于肿瘤靶向治疗的白细胞介素15融合蛋白
US10611812B2 (en) 2015-07-02 2020-04-07 Numab Biopharmaceuticals (Hangzhou) Ltd. Interleukin 15 fusion protein for tumor targeting therapy
US11236140B2 (en) 2015-07-02 2022-02-01 Bj Bioscience Inc. Interleukin 15 fusion protein for tumor targeting therapy
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
CN112105631A (zh) * 2018-03-06 2020-12-18 约翰霍普金斯大学 Treg耗尽和检查点抑制剂的组合
CN113354738A (zh) * 2020-03-05 2021-09-07 宁波德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
CN113354738B (zh) * 2020-03-05 2022-09-09 绍兴德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
CN114681599A (zh) * 2020-12-31 2022-07-01 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
CN114681599B (zh) * 2020-12-31 2024-07-02 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
CN117384859A (zh) * 2023-12-13 2024-01-12 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用

Also Published As

Publication number Publication date
PL397167A1 (pl) 2013-06-10
IN2014CN04498A (https=) 2015-09-11
EA201491049A1 (ru) 2014-10-30
SG11201402312WA (en) 2014-06-27
EP2785362A2 (en) 2014-10-08
MX2014006369A (es) 2014-07-09
KR20140097529A (ko) 2014-08-06
PH12014501083A1 (en) 2014-08-04
CA2856480A1 (en) 2013-06-06
ZA201404667B (en) 2015-09-30
AU2012345494A1 (en) 2014-07-10
IL232743A0 (en) 2014-07-31
WO2013080147A3 (en) 2014-02-13
US20150044162A1 (en) 2015-02-12
HK1201727A1 (en) 2015-09-11
BR112014012808A2 (pt) 2019-09-24
JP2015500228A (ja) 2015-01-05
WO2013080147A2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
CN103974711A (zh) 抗癌融合蛋白
CN103228788B (zh) 抗癌融合蛋白
CN102958940B (zh) 抗癌融合蛋白
CN103987728B (zh) 抗癌融合蛋白
CN103237808B (zh) 抗癌融合蛋白
CN103562220A (zh) 抗癌融合蛋白
WO2015143581A1 (zh) 靶特异性双突变体融合蛋白质及其制备工艺
NZ627445B2 (en) Anticancer fusion protein
HK1201848B (en) Anticancer fusion protein
HK1186209B (en) Anticancer fusion protein
HK1186209A (en) Anticancer fusion protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140806